Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm (1)
Mandate

Vinge advises Vicore Pharma in connection with its listing on Nasdaq Stockholm

September 23, 2019 Capital Markets and Public M&A

Vinge advises Vicore Pharma Holding AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market.

The prospectus was published on 16 September 2019 and the trading on Nasdaq Stockholm will commence on 27 September 2019.

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs in preclinical or clinical phase.

Vinge’s team has primarily consisted of Jesper Schönbeck, Nils Fredrik Dehlin, Astrid Isberg, Emelie Svanberg, Viktor Bergsten and Sofia Bergenstråhle.

Related

Vinge advises on the sale of RK Projektledning to Qflow

 Vinge has advised the sellers in connection with the sale of all shares in RK Projektledning AB to Qflow Group.
December 05, 2025

Vinge represents IKEA Forestry Investment AB in connection with the acquisition of forest land in Latvia and Lithuania

 Vinge assists IKEA Forestry Investment AB (a company within the Inter IKEA group) in the acquisition of a Latvian and a Lithuanian company from Dasos Timberland Fund II (a fund managed by CapMan Natural Capital).
December 05, 2025

Vinge advises and Valcon in connection with the acquisition of Bricobomba

Bricobomba AB is a Swedish company with expertise in data and AI. The acquisition will strengthen Valcon’s capacity in the Nordic region and further expand the company’s ability to deliver comprehensive data and AI-based services to its customers on a pan-European scale.
December 05, 2025